Drug Interactions between Copper and patiromer

Patiromer may bind to many different oral medications in the gastrointestinal tract and reduce their absorption into the blood stream. The effectiveness of some oral medications may be decreased when taken with patiromer. To minimize the possibility of interaction, it is recommended that you separate the dosing times of patiromer and any oral medication you take by at least three hours. Talk to your doctor if you are unable to do so or if you have other questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions. Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.

The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions. Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia. It is recommended to monitor serum magnesium concentrations during therapy. Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency. Consider magnesium supplementation in patients who develop low serum magnesium levels.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia. It is recommended to monitor serum magnesium concentrations during therapy. Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency. Consider magnesium supplementation in patients who develop low serum magnesium levels.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.